TONIX PHARMACEUTICALS

Other languages Tonix Pharmaceuticals Nasdaq

Equities

TNXP

US8902608624

End-of-day quote Nasdaq Other stock markets 04:30:00 05/02/2024 am IST			5-day change	1st Jan Change
0.3222 ^USD	-2.36%		+2.32%	-20.05%

01/04	Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
01/04	Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02/04
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
Tonix Pharmaceuticals Prices $4.4 Million Direct Offering; Revises Existing Warrant Terms -- Shares Tumble	28/03
Tonix Pharmaceuticals Gets Rare Pediatric Disease Label For TNX-2900 to Treat Prader-Willi Syndrome	25/03
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society Spring 2024 Meeting	21/03
Tonix Pharmaceuticals Reports Improvement in ?Brain Fog,? in Fibromyalgia Patients Treated with Tonmya? in Resilient, an Nda-Enabling Phase 3 Clinical Trial	11/03
Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy	07/03
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans	05/03
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-Modified Humanized Anti-CD40L mAb) in Healthy Volunteers	28/02
Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya? to Support Development and Partnering in Japan and China	27/02
Tonix Pharmaceuticals Reports Positive Phase 3 Study Results for Its Non-Opioid Painkiller in Late December	15/02
Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya?, Plans to File NDA for FDA Approval in Second Half of 2024	14/02
Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Response and Prevention of PTSD	12/02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer